George Moanaroa believes the spiritual world of Te Ao Māori and the medical world joined forces to save his life. Moanaroa ...

Affected populations: Acromegaly is estimated to affect approximately 50 to 70 people out of every million. However, the true figure may be higher, as the symptoms develop slowly and thus may go ...

Acromegaly is a rare endocrine disease generally caused by a pituitary adenoma, which is a non-cancerous tumor in the pituitary that secretes growth hormone. The PATHFNDR-2 study is evaluating ...

The Acromegaly Consensus Group considered many of the advances that have occurred in the management of acromegaly over the past 10 years. First, the growth hormone receptor antagonist pegvisomant ...

ProBioGen and Marea Therapeutics Inc. have successfully completed a sprint project to deliver clinical material for MAR002.

“The acceptance of our NDA for paltusotine in acromegaly was a key achievement, and under the leadership of our new chief commercial officer, Isabel Kalofonos, our commercial team is preparing for the ...

The partnership focused on an integrated and accelerated chemistry, manufacturing, and controls (CMC) program for MAR002, Marea's investigational anti-growth hormone receptor (GHR) antibody for the ...

A generic version of a treatment for acromegaly is now available for adults in the U.S., according to an industry press release. Adults diagnosed with endogenous Cushing’s syndrome have a higher ...

Biochemical control of acromegaly in noncured patients is usually defined as serum growth hormone (GH) levels <2.0 µg/l, plus normal-for-age serum levels of insulin-like growth factor I (IGF-I).